

PLOS ONE publishes results that highlights the role of BSSL in inflammatory joint disorders

Lipum AB (publ) today reported that the scientific publication titled “Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders” was published in the peer-reviewed, open access journal PLOS ONE. The authors are researchers at Lipum AB, together with collaborators at the Departments of Public Health and Clinical Medicine, Rheumatology and Clinical Sciences, Pediatrics, Umeå University, Sweden.

The publication provides data showing that BSSL (bile salt-stimulated lipase) levels are significantly higher in blood samples from patients with rheumatoid arthritis and psoriatic arthritis compared with healthy controls and reveals significant correlations between BSSL levels in the blood and disease activity scores and other established inflammatory markers.

Further, the publication details interactions and effects of BSSL on human inflammatory cells and show that the protein is secreted by granulocytes, binds to monocytes, and stimulates cell migration *in vitro*. Moreover, it shows that antibodies that block the interaction between BSSL and monocytes simultaneously prevent BSSLs capacity to induce cell migration.

“The article summarize our preclinical research showing that BSSL is a proinflammatory component of the innate immune system involved in the recruitment of inflammatory cells to a site of inflammation, fully consistent with BSSL as a promising new target for the treatment of chronic inflammation”, said Susanne Lindquist, CSO.

Read the article “Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders” by S Lindquist *et al* [here](#).

Contacts

Dr. Susanne Lindquist, CSO

info@lipum.se

+46 90 340 34 30

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

14 August 2023 07:30:00 CEST



Attachments

[PLOS ONE publishes results that highlights the role of BSSL in inflammatory joint disorders](#)